Lifeboat Foundation

The U.S. Food and Drug Administration announced on Oct. 27 that it has approved, for the first time, an oncolytic (cancer-killing) viral therapy in the United States. The drug was approved for use against late-stage melanoma, a deadly skin cancer that can be difficult to treat.

The approval came as the result of a recent Phase III study, which showed that more patients with late-stage melanoma, treated with a herpes cold sore virus designed to kill tumor cells, had a better response when compared to a different treatment. Robert Andtbacka, M.D., from Huntsman Cancer Institute at the University of Utah and Howard L. Kaufman, M.D., from Rutgers Cancer Institute of New Jersey, led the multisite study, published May 26 online in the Journal of Clinical Oncology.

According to Andtbacka, “The goal of this targeted therapy is to treat late stage patients more effectively and with fewer side effects.”

Read more

These people have got a leg — or an arm — up on the future.

Thanks to the latest advancements in medical science, amputees are becoming part robot, with awe-inspiring artificial limbs that would make Luke Skywalker jealous.

These new limbs come armed with microprocessors and electrodes that sense muscle movement. Others can be controlled by a smartphone app. People missing limbs often tried to hide their prosthetics, but these New Yorkers are showing them off with pride.
Rebekah Marine.

Continue reading “Are these artificial limbs better than the real thing?” »

A very interesting article about the state of funding for aging research and about Buck and ex Geron Mike West.

As I mentioned in last week’s letter, I traveled to San Francisco last Monday with my friend Patrick Cox, who writes our Transformational Technology Alert newsletter. We had dinner with Dr. Mike West of Biotime and then spent the next morning at the Buck Institute for Research on Aging. Pat and I decided we would jointly report on what we learned. He has already written his part, which was published last week. I am going to reproduce portions of that letter, which highlight the conversation with Brian Kennedy and his team at the Buck Institute, and then add my own thoughts about our conversation with Mike West the previous night.

(Note that I am excerpting Patrick’s paid letter, which includes comments on companies in his portfolio, rather than his free weekly Transformational Technologies Tech Digest service. We agreed that it was important to do so in this one case, given the huge significance of the research involved and the Buck Institute’s relationship to it.)

Continue reading “The ‘Age’ Age” »

Current medical treatment boils down to six words: Have disease, take pill, kill something. But physician Siddhartha Mukherjee points to a future of medicine that will transform the way we heal.

TEDTalks is a daily video podcast of the best talks and performances from the TED Conference, where the world’s leading thinkers and doers give the talk of their lives in 18 minutes (or less). Look for talks on Technology, Entertainment and Design — plus science, business, global issues, the arts and much more.

Continue reading “Soon We’ll Cure Diseases With a Cell, Not a Pill | Siddhartha Mukherjee | TED Talks” »

This is our chance to make a real difference to how ageing research progresses and how people view ageing.

We need fifty people to make a real change in funding policy so we can work towards healthy longevity.

https://www.facebook.com/…/draft-zero-gsap-ageing-and-healt… (please make sure to complete the 6 first lines at least before sending to the email indicated there).

WHO GSAP draft, healthy longevity and biomedical aging research.

Read more

More *!* — WOW — *!*
How can anyone NOT love science?!

Holograms (3-D light fields) can be projected from a 2-dimensional surface to control objects. (credit: Asier Marzo, Bruce Drinkwater and Sriram Subramanian)

Continue reading “Holographic sonic tractor beam lifts and moves objects using soundwaves” »

What is Ouro_botics?

Ouro_botics started life around four years ago on a kitchen table in Dublin.

Founder Jemma Redmond was working at the time on her masters thesis “An Investigation into Osteoblast Adhesion” and printed copies of finger bones (metacarpals, proximal & distal phalanges) which she then seeded with Osteoblasts and noticed growth was affected by structure.

Read more

Losing hair can be a distressing experience for many people, but treatments are often ineffective, expensive or riddled with side effects. Could this development change that?

A study from Colombia University has shown blocking a certain family of enzymes can rapidly restore hair. The enzymes are called the Janus kinase (JAK) family, and two drugs have already been approved for blood diseases (ruxolitinib) and rheumatoid arthritis (tofacitinib), and are also undergoing other clinical trials.

Read more

Viruses are usually thought of as agents of disease. But for the first time, scientists are poised to bring to the US market a virus that can help thwart cancer, a development that could herald a new age of viral therapies.

Approved by the Food and Drug Administration on Tuesday for treating advanced-stage melanoma, the virus — called Imlygic, which was developed in part in a Massachusetts lab — is a modified version of the herpes virus that both attacks the cancer and sparks the immune system into action against tumors.

In clinical trials, it has helped some cancer patients achieve remission with few of the nasty side effects common to existing treatments. And as the first tumor-killing virus to receive the FDA’s blessing, Imlygic could accelerate the development of other viral therapies.

Read more